GVR Report cover Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Report

Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Condition (Myeloma, Lymphoma, Breast Cancer), By Linker (Cleavable Linker, Non-cleavable Linker), By Region, And Segment Forecasts, 2021 - 2028

  • Published Date: Sep, 2021
  • Base Year for Estimate: 2020
  • Report ID: GVR-4-68039-623-5
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2019
  • Number of Pages: 110

Report Overview

The global antibody drug conjugates contract manufacturing market size was valued at USD 7.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 12.3% from 2021 to 2028. The market is anticipated to witness significant growth over the forecast period on account of the increasing prevalence of cancer, rising demand for biologic therapy, and outsourcing of operations and services to contract manufacturing organizations.

U.S. antibody drug conjugates contract manufacturing market size, by condition, 2018 - 2028 (USD Million)

Many cancer medicines have toxicities that cause substantial side effects, limiting the dosage and efficacy of these medications and placing a significant burden on patients. An antibody drug conjugate can help to reduce some of these complications. Antibody Drug Conjugates (ADC) enable the delivery of particular medication dosage to a specific site of interest. They are most often used in oncology when a large medication dosage is required at the tumor site but not in nearby tissue.

COVID-19 has had a massive influence on the healthcare domain, significantly disrupting the whole supply chain, from raw materials to production and delivery. Major market players are active in research and development activities, strategic alliances and collaborations, and new product launches to meet consumer needs for medicines, vaccines, diagnostics, and medical equipment.

CMOs provide technical knowledge in conjugation and linker creation, as well as solid platforms. Using an integrated CMO decreases an ADC's time to market since they can handle all stages such as conjugation, scale-up, commercial production, and ADC fill-finish, saving time in scheduling and testing. In October 2018,ImmunoGen switched its ADC manufacturing operations to an outsourced model, citing the benefit of having more access to the expertise that a CMO offers, resulting in a $20 million savings.

The active pharmaceutical ingredient (API) industry, which has traditionally been dominated by small-molecule medicines, is rapidly shifting towards biopharmaceuticals. Similarly, the volume of production outsourced to contract manufacturing businesses is increasing. Due to the complexity of manufacturing methods and concerns about intellectual property, biologicals are now primarily made in-house by drug producers, which has a knock-on impact on contract manufacturing organizations.

Condition Insights

The myeloma segment dominated the market and accounted for the largest revenue share of 49.4% in 2020. The factors that influence market growth are antibody drug conjugates, which is a novel type of treatment for myeloma patients that deliver a powerful cytotoxic chemical directly to the myeloma cell.

The specificity of the monoclonal antibody linked to the cytotoxic chemical defines the target. This mode of action reduces bystander cell damage and opens up a therapeutic window. ADCs have a high potential for use in the treatment of myeloma as it is 'off the shelf' therapies. It can be utilized in almost all myeloma treatment clinics and to a diverse spectrum of patients.

Linker Insights

The cleavable linker segment dominated the market for ADC contract manufacturing and accounted for the largest revenue share of 56.5% in 2020. The segment is likely to remain dominant in the coming future. Major factor that influences the growth in the segment is the advantages that cleavable linkers take in certain circumstances to deliver the medication to the target cell. The characteristics of the linker between the antibody and the payload are seen to be crucial to an ADC's success. The capacity of cleavable linkers to efficiently distinguish between circulatory and target-cell circumstances accounts for its effectiveness.

The non-cleavable linker segment is projected to witness the fastest CAGR of 12.5% over the forecast period. ADCs with non-cleavable linkers are more reliant on the target cells' biology. Non-cleavable linkers have higher plasma stability than cleavable linkers, which can help to enhance the therapeutic index.

Regional Insights

Asia Pacific dominated the ADC contract manufacturing market and accounted for the largest revenue share of 46.4% in 2020. The region is projected to witness the fastest growth rate of 14.6% over the forecast period. Asia Pacific accounts for 48.0% of all new cancer cases worldwide, with China accounting for nearly half of all cases. Similarly, cancer fatalities in Asia account for 55.0% of all cancer deaths worldwide. Over the next two decades, cancer incidence and death are anticipated to increase in Asia.

Global antibody drug conjugates contract manufacturing market share, by region, 2020 (%)

Asia Pacific is the world's fastest-growing pharmaceutical market, with huge potential for medication research and commercialization. As a result, pharmaceutical regulations in this region are attracting a lot of attention from pharmaceutical firms all over the world. The factor responsible for the growth of the market in the region is the increase in the outsourcing operations to contract manufacturing organizations.

Key Companies and Market Share Insights

Strategic alliances in the form of mergers and acquisitions, collaborations, partnerships with other market players, and increasing R&D in the area of antibody drug conjugates for cancer medications are some of the initiatives being undertaken by key players in order to increase their share in the market. In August 2019, Cambrex Corporation declared that it has signed a formal agreement to be purchased by a Permira funds subsidiary in a transaction valued at $2.4 billion. Cambrex is in a unique position during a pandemic, assisting innovators with clinical trial materials for COVID-19 purposes while also handling significant pressure in delivering goods in the midst of raw material and supply chain shortages. Some of the prominent players in theantibody drug conjugates contract manufacturing market include:

  • Samsung Biologics

  • Lonza

  • Catalent

  • Siegfried

  • Piramal Pharma Solutions

  • Boehringer Ingelheim

Antibody Drug Conjugates Contract Manufacturing Market Report Scope

Report Attribute

Details

Market Size value in 2021

USD 8.2 billion

Revenue forecast in 2028

USD 18.4 billion

Growth rate

CAGR of 12.3% from 2021 to 2028

Base year for estimation

2020

Historical data

2016 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Condition, linker, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; India; Japan; China; Australia; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

Key companies profiled

Cambrex; ReciPharm; ThermoFisher; Pantheon; Corden Pharma; Samsung Biologics; Lonza; Catalent; Siegfried; Piramal Pharma Solutions; Boehringer Ingelheim

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research, Inc. has segmented the global antibody drug conjugates contract manufacturing market report on the basis of condition, linker, and region:

  • Condition Outlook (Revenue, USD Million, 2016 - 2028)

    • Myeloma

    • Lymphoma

    • Breast Cancer

    • Others (Urothelial Cancer)

  • Linker Outlook (Revenue, USD Million, 2016 - 2028)

    • Cleavable Linker

    • Non-cleavable Linker

  • Regional Outlook (Revenue, USD Million, 2016 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East and Africa (MEA)

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.